Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go

被引：47
|
作者：
Lv, Meng [1 ]
Huang, Xiao-Jun [1 ]
机构：
[1] Peking Univ, Inst Hematol, Peoples Hosp, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing 100044, Peoples R China
来源：
JOURNAL OF HEMATOLOGY & ONCOLOGY | 2012年 / 5卷
基金：
中国国家自然科学基金;
关键词：
China; Allo-HSCT; Haploidentical; Relapse; GVHD; Elderly patients; ACUTE MYELOID-LEUKEMIA; BONE-MARROW-TRANSPLANTATION; DONOR LYMPHOCYTE INFUSION; RISK ACUTE-LEUKEMIA; ACUTE GVHD; ANTITHYMOCYTE GLOBULIN; MYCOPHENOLATE-MOFETIL; CLINICAL-OUTCOMES; T-CELLS; BLOOD;
D O I：
10.1186/1756-8722-5-10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective and sometimes the only curative therapy for patients with certain hematological diseases. Allo-HSCT has been practiced in China for approximately 30 years, and great improvements have been made within the past decade, particularly in fields such as the haploidentical HSCT system, strategies to overcome relapse and GVHD, and modified HSCT for elderly patients. This review will describe the current situation and provide a prospective of these unique aspects of Allo-HSCT in China.
引用
收藏
页数：8
相关论文
共 50 条
  • [11] Gut microbiota and hematopoietic stem cell transplantation: where do we stand?
    D Zama
    E Biagi
    R Masetti
    P Gasperini
    A Prete
    M Candela
    P Brigidi
    A Pession
    Bone Marrow Transplantation, 2017, 52 : 7 - 14
  • [12] Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: Where do we go from here?
    Chakrabarti, S
    Hale, G
    Waldmann, H
    TRANSPLANTATION PROCEEDINGS, 2004, 36 (05) : 1225 - 1227
  • [13] Stem Cell Therapy in Bladder Dysfunction: Where Are We? And Where Do We Have to Go?
    Kim, Jae Heon
    Lee, Sang-Rae
    Song, Yun Seob
    Lee, Hong Jun
    BIOMED RESEARCH INTERNATIONAL, 2013, 2013
  • [14] Stem cells in multiple sclerosis: where we are and where we go
    Martino, G.
    JOURNAL OF NEUROLOGY, 2012, 259 : S6 - S6
  • [15] Hematopoietic stem cell transplantation and cellular therapy in sickle cell disease: where are we now?
    Tanhehco, Yvette C.
    Bhatia, Monica
    CURRENT OPINION IN HEMATOLOGY, 2019, 26 (06) : 448 - 452
  • [16] Translating transplantation tolerance in the clinic: where are we, where do we go?
    Goldman, M.
    Wood, K.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2009, 156 (02): : 185 - 188
  • [17] Neural stem cells in multiple sclerosis: where we are, where we go
    Martino, G
    MULTIPLE SCLEROSIS, 2005, 11 : S15 - S15
  • [18] Transplant of hematopoietic stem cells in childhood: where we are and where we are going
    Locatelli, F
    Burgio, GR
    HAEMATOLOGICA, 1998, 83 (06) : 550 - 563
  • [19] Hematopoietic stem cell transplantation in 2012: Who? Where? How?
    Dalle, J-H.
    ARCHIVES DE PEDIATRIE, 2013, 20 (04): : 405 - 411
  • [20] STEM CELL GENE THERAPY FOR PRIMARY IMMUNODEFICIENCY DISEASES: WHERE ARE WE TODAY AND WHERE SHOULD WE GO?
    Otsu, Makoto
    JOURNAL OF GENE MEDICINE, 2014, 16 (7-8): : 216 - 217
12345